Navigation Links
Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Date:4/27/2009

of testosterone.(1)(2) Suppression of testosterone to castrate levels occurred significantly faster in patients receiving degarelix than in those receiving leuprolide.(1)(2) At Day 3 of treatment, the degarelix group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels, a statistically significant result. Degarelix was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the degarelix patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.

In addition, prostate-specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of degarelix, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.(1)(2) These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit.

About Degarelix

Degarelix is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. As a receptor antagonist, degarelix reversibly binds to the GnRH receptors in the pituitary gland, immediately suppressing the secretion of the luteinizing hormone (LH), follicle-stimulating hormone (FSH), and subsequently, testosterone levels.(3) Degarelix also reduces levels of prostate-specific antigen (PSA). Unlike luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, an established treatment for prostate cancer, degarelix does not induce an initial testosterone surge. Degarelix is administered monthly by subcutaneous injection. The starting dose is 240 mg, fol
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
(Date:10/22/2014)... Mass. and SHANGHAI , ... (NASDAQ: FMI ) and WuXi PharmaTech ... a collaboration to offer Foundation Medicine,s comprehensive genomic profiling ... China . Under the terms ... WuXi to perform the laboratory component of Foundation Medicine,s ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... , Event to Highlight Progress in Research, Advocacy and New Treatments , ... WASHINGTON , May 11 The National Organization for ... that have brought innovative new treatments to market for rare diseases at the 2010 NORD ... on Tuesday, May 18 . , , ...
... U.S. Food and Drug Administration recently approved an application that permits B. Braun ... Injection USP and Dextrose Injection USP in B. Braun,s DUPLEX® Drug Delivery System ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) ... Used in hospitals and healthcare centers ...
Cached Medicine Technology:NORD to Honor Rare Disease Innovators 2NORD to Honor Rare Disease Innovators 3NORD to Honor Rare Disease Innovators 4FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 2FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter , ... young adult men may lead to increased blood pressure, according ... a similar rise in blood pressure for young adult women ... young adult women drank lightly or moderately, their risk of ... "This finding parallels studies in older adult men and ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Blanket Limbo to raise funds for amputees DALLAS, Feb. 18 ... arm or a leg. Of those impacted, many find themselves with ... limbs needed to resume their daily lives. , ... awareness to the plight of these amputees and provide them with ...
... save lives by donating blood regularlySEWELL, N.J., Feb. 18 ... February 21, 2009 from 9:00 a.m. to 3:00 p.m. ... To make an immediate appointment for this blood ... )Koerner is battling a type of cancer called Acute ...
... 18 The ,Help is Here Express, bus tour ... February 23-27 at various cities throughout the state ... information on programs that provide prescription medicines for free ... having risen for seven straight months, standing today at ...
... widely used blood pressure medication may be the key ... according to a newly published study by researchers at ... offer the hope of an improved quality of life ... study drew on a hypothesis from previous studies that ...
... Ill., and Osaka, Japan, February 13, 2009 Takeda ... North America, Inc., announced today that the United States ... 40 mg and 80 mg for the chronic management ... medication is the first new treatment option in more ...
... clinicians and researchers in the bone health field ... held from March 18-21 in Athens, Greece. ... four-day meeting which will feature an expanded scientific ... clinically-oriented ,Meet-the-Professor, sessions. The programme is also enhanced ...
Cached Medicine News:Health News:Limbs for Life Foundation to Host 8th Annual Fundraiser and Live Auction 2Health News:Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner 2Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Texas Workers Hurt by Recession 4Health News:Blood pressure compound may benefit brain tumor patients 2Health News:Blood pressure compound may benefit brain tumor patients 3Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 2Health News:FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: